Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coversin long-term safety and efficacy surveillance study
NL-OMON48556Phase 3Completed
- Sponsor
- Akari Therapeutics
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of nomacopan in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), sponsored by Akari Therapeutics. Primary endpoint: Long-term safety of Coversin. Started Mar 2018; status: completed.
02
Drugs
nomacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NL-OMON48556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48556.